Citations

Clear

1134 citation(s) found for "Yan, Di".

Opportunities and Challenges of Observational Studies and Randomized Controlled Trials for Evaluating the Therapeutic Efficacy of COVID-19 Convalescent Plasma
Desai, Aakash , Leyfman, Yan , Kuderer, Nicole M. , Desai, Aakash P , Leyfman, Yan , Lyman, Gary H

Mayo Clinic

Cancer Investigation | June 17, 2021 | Volume: 39 | Issue: 6-7 | Pages: 449-456

10.1080/07357907.2021.1942127 | PMID 34134587 Get It

Abstract B15: Dabrafenib-trametinib-induced pyrexia successfully treated with colchicine
Vera, Jesus Diaz , Kottschade, Lisa A. , Block, Matthew S. , Yan, Yiyi , Loprinzi, Charles L. , Markovic, Svetomir, Paludo, Jonas , Markovic, Svetomir N.

Mayo Clinic

Molecular Cancer Research | June 10, 2021 | Volume: 18 | Issue: 5_Supplement | Pages: B15-B15

10.1158/1557-3125.ras18-b15 Get It

Abstract The most common adverse event (AE) of dabrafenib and trametinib (DT) is pyrexia, which has been reported to occur in up to 71% of patients. Pyrexia resulted in therapy discontinuation in up to 26% of patients who otherwise were benefiting from the treatment. Little is known about the pathogenesis and optimal management of this common AE. We hypothesized that the etiology of pyrexia in patients treated with DT could be extrapolated from DT-related cutaneous adverse effects in which a paradoxical MAPK pathway activation has been identified. We hypothesized that the mechanism of MAPK pathway activation with DT therapy is similar to that reported in patients with familial Mediterranean fever (FMF), a rare, inherited condition characterized by episodes of fever and rash that responds exceedingly well to colchicine-based therapy. Based on this association, our group explored the use of oral colchicine for the treatment of DT-associated pyrexia in five patients with metastatic melanoma. Citation Format: Jesus Vera, Jonas Paludo, Lisa Kottschade, Matthew Block, Yiyi Yan, Charles Loprinzi, Svetomir Markovic. Dabrafenib-trametinib-induced pyrexia successfully treated with colchicine [abstract]. In: Proceedings of the AACR Special Conference on Targeting RAS-Driven Cancers; 2018 Dec 9-12; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Res 2020;18(5_Suppl):Abstract nr B15.
Does Proton Pump Inhibitor Use Lead to a Higher Risk of Coronavirus Disease 2019 Infection and Progression to Severe Disease? a Meta-analysis
Yan, Cunye, Chen, Yue , Sun, Chenyu , Bhan, Chandur , Guo, Zhichun , Yang, Hongru , Zuo, Yijing , Yan, Yue , Hu, Lei , Sun, Yiceng , Li, Yao , Zhou, Qin , Sun, Chenyu , Ahmed, Mubashir Ayaz

Mayo Clinic

Japanese Journal of Infectious Diseases | May 30, 2021 | Volume: 75 | Issue: 1 | Pages: 10-15

10.7883/yoken.jjid.2021.074 | PMID 34053958 Get It

Flap Reconstruction for Treatment of Pediatric Linear Scleroderma
Yan, María , Stans, Anthony A. , Moran, Steven L.

Mayo Clinic

Annals of Plastic Surgery | May 24, 2021 | Volume: 87 | Issue: 5 | Pages: 533-536

10.1097/sap.0000000000002887 | PMID 34699432 Get It

Background Linear scleroderma is a rare connective tissue disease characterized by thickening of the skin due to excess collagen deposit. It is the most frequent type of localized scleroderma in the pediatric population (40%–70%), and it usually affects the extremities and head. Linear scleroderma can cause growth disturbances, extremity length discrepancy, and debilitating joint contractures. The aim of this study was to describe the surgical outcomes of microsurgical flap reconstruction of linear scleroderma in the pediatric population. Methods A retrospective review of all children with linear scleroderma was performed at our institution. Patients less than 18 years of age with clinical diagnosis of linear scleroderma and who underwent microsurgical flap reconstruction for correction of their scleroderma were included. Fat grafting procedures were excluded. Patient demographics and surgical outcomes were collected. Results A total 7 patients underwent microsurgical flap reconstruction for treatment of their linear scleroderma producing debilitating soft tissue contractures and preventing ambulation or elbow extension. Six patients had scleroderma involving the lower extremity and 1 involving the upper extremity. Three anterolateral thigh and 4 latissimus dorsi flaps were performed. The median age at surgery was 7 years (Q1–Q3, 5–11), and the median body mass index was 21.3 kg/m2 (Q1–Q3, 16.5–22.1). The median follow-up was 121.1 months (Q1–Q3, 43.2–187.4). All flaps survived, and no donor site complications were reported. Perioperative complications included wound infection that required debridement (n = 1), immediate postoperative bleeding requiring surgical intervention (n = 1), intraoperative venous congestion (n = 1), and scleroderma recurrence outside the flap (n = 2). When comparing anterolateral thigh and latissimus dorsi flaps, there was no statistically significant difference in the development of surgical complications, number of surgical revisions per patient [median, 4 (Q1–Q3, 4–7) vs 2.5 (Q1–Q3, 1.3, 3), P = 0.0916], or unplanned surgical interventions [median, 0 (Q1–Q3, 0–1) vs 1 (Q1–Q3, 0–1), P = 0.7228]. The reconstruction was successful in improving range of motion in 6 patients, 5 of which reached full weight-bearing. However, all patients had residual limb deformity, and 4 had remaining extremity length discrepancy. Conclusions Microsurgical flaps are a good option for functional improvement of severe pediatric linear scleroderma affecting the extremities. However, residual limb deformity is common, and patients are often required to undergo additional surgical revisions.
Thinking Outside the Field: Two Cases of RT+ICI Synergy in Melanoma
Davidson, Tara M. , Yan, Yiyi , Zhang, Henan , Dong, Haidong , Grams, Michael P. , Park, Sean S.

Mayo Clinic

No container title available | May 17, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-455431/v1 Get It

Abstract While combination radiotherapy (RT) and immunotherapy is not novel there is still much to learn about this approach. Some initial pre-clinical and clinical evidence suggests triple therapy with RT and dual immune checkpoint blockade (anti-CTLA-4 + anti-PD-1/PD-L1) is a complimentary technique. We present two cases using the same novel regime of combination RT plus nivolumab and ipilimumab to treat metastatic melanoma. In both cases the burden of disease was significant within a lower extremity. Additionally, in both cases using this treatment plan, we were able establish sustained local disease control with additional systemic benefit which allowed both patients to avoid significant debility from surgical amputation. Given the response and safety we observed, this technique could be used as a potentially safe approach for future patients who are not eligible for traditional RT palliation or clinical trials.
Treatment Approach of Refractory Helicobacter pylori Infection : A Comprehensive Review
Cortés, Pedro , Nelson, Alfred D. , Bi, Yan , Murray, Loren P., Gómez, Victoria , Harris, Dana M. , Stancampiano, Fernando F , Harris, Dana M , Cortés, Pedro , Stancampiano, Fernando F. , Pujalte, George G.A.

Mayo Clinic

Journal of Primary Care & Community Health | May 9, 2021 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/21501327211014087 | PMID 33949229 Get It

H. pylori is the most common infection in the world and is associated with gastrointestinal and extra-gastrointestinal manifestations, including peptic ulcer disease, gastrointestinal bleeding, and lymphoproliferative disorders. Despite being discovered less than half a century ago, antibiotic resistance, exacerbated by medication non-adherence and inefficacy of proton pump inhibitors, has grown substantially, explaining the rising incidence of refractory H. pylori infection. In this review, we discuss risk factors, treatment options, surveillance and follow-up, as well as emerging therapies for refractory H. pylori.
Outcome Analysis of Free Flaps in Patients With Collagen Vascular Disorders: 10-year Single Institution Review
Singh, Kuldeep , Carlsen, Brian T. , Moran, Steven L. , Vijayasekaran, Aparna , Yan, María

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | May 7, 2021 | Volume: 8 | Issue: 9S | Pages: 83-84

10.1097/01.gox.0000720728.23377.ca Get It

British Society of Gastroenterology guidelines on the management of irritable bowel syndrome
Vasant, Dipesh H. , Paine, Peter , Black, Christopher J. , Houghton, Lesley A. , Everitt, Hazel , Corsetti, Maura , Aziz, Imran , Farmer, Adam D. , Eugenicos, Maria , Moss‐Morris, Rona , Yiannakou, Yan , Ford, Alexander C. , Aziz, Imran , Ford, Alexander C , Houghton, L A , Corsetti, M , Black, Christopher J , Vasant, Dipesh H , Farmer, Adam D , Agrawal, Anurag

Mayo Clinic

Gut | April 26, 2021 | Volume: 70 | Issue: 7 | Pages: 1214-1240

10.1136/gutjnl-2021-324598 | PMID 33903147 Get It

Irritable bowel syndrome (IBS) remains one of the most common gastrointestinal disorders seen by clinicians in both primary and secondary care. Since publication of the last British Society of Gastroenterology (BSG) guideline in 2007, substantial advances have been made in understanding its complex pathophysiology, resulting in its re-classification as a disorder of gut-brain interaction, rather than a functional gastrointestinal disorder. Moreover, there has been a considerable amount of new evidence published concerning the diagnosis, investigation and management of IBS. The primary aim of this guideline, commissioned by the BSG, is to review and summarise the current evidence to inform and guide clinical practice, by providing a practical framework for evidence-based management of patients. One of the strengths of this guideline is that the recommendations for treatment are based on evidence derived from a comprehensive search of the medical literature, which was used to inform an update of a series of trial-based and network meta-analyses assessing the efficacy of dietary, pharmacological and psychological therapies in treating IBS. Specific recommendations have been made according to the Grading of Recommendations Assessment, Development and Evaluation system, summarising both the strength of the recommendations and the overall quality of evidence. Finally, this guideline identifies novel treatments that are in development, as well as highlighting areas of unmet need for future research.